Pharmacogenomic research and serum DNA analysis in the treatment of non-small cell lung cancer

Clinical and Translational Oncology

Volumn 3, Issue 2, 2001, Pages 60-71

  Rosell, Rafael ^a   O'Brate, Aurora ^a   Monzó, Mariano ^a   Miguel Sánchez, José ^a   Guillot, Mónica ^a   Jassem, Jacek ^b   Javier Sánchez, José ^c   Abad, Albert ^a   Escuin, Daniel ^a   Tarón, Miquel ^a   Jassem, Ewa ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c Polytechnic of Madrid University   (Spain)

Author keywords

Dynamics; Microtubule; P53; Paclitaxel resistance; Ras mutations; Tubulin mutation

Indexed keywords

EID: 84873401924     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-smallcell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4: 1.604-1.614.
2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1.618-1.626.
3. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13: 1.221-1.230.
4. Lilenbaum RC, Langerberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. A metaanalysis of response, toxicity and survival. Cancer 1998; 82: 116-126.
5. Strauss BS. The origin of point mutations in human tumor cells. Cancer Res 1992; 52: 249-253.
6. Rosenthal N, Schwartz RS. In search of perverse polymorphisms. N Engl J Med 1998; 338: 122-124.
7. INK4a/ CDKN2A in human glioma. Oncogene 1997; 14: 603-609.
8. INK4a/CDKN2A: correlation with protein structure information. Oncogene 1999; 18: 5.423-5.434.
9. Schena M, Shalon D, Heller R, et al. Parallel human genome analysis: microarray-based expression monitoring of 1,000 genes. Proc Natl Acad Sci USA 1996; 93: 10.614-10.619.
10. Heller RA, Schena M, Chai A, et al. Discovery and analysis of inflammatory disease-related geles using cDN A microarrays. Proc Natl Acad Sci USA 1997; 94: 2.150-2.155.
11. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
12. Shan B, Medina JC, Santha E, et al. Selective, covalent modification of â-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc Natl Acad Sci USA 1999; 96: 5.686-5.691.
13. Duan Z, Feller AJ, Penson RT, et al. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999; 5: 3.445-3.453.
14. Mitsudomi T, Steinberg SM, Oie HK, et al. Ras gene mutations in non-small-cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4.999-5.002.
15. Rodenhuis S, Boerrigter L, Top B, et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 1997; 15: 285-291.
16. Tsai CM, Chang KT, Perng RP, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897-901.
17. Rosell R, Li S, Anton A, et al. Prognostic value of Kras 12 genotypes in patients with advanced nonsmall-cell lung cancer receiving carboplatin with either intravenous or chronic oral dose etoposide. Int J Oncol 1994; 5: 169-176.
18. Rosell R, Monzó M, Pifarré A, et al. Molecular staging of non-small-cell lung cancer according to K-ras genotypes. Clin Cancer Res 1996; 2: 1.083-1.086.
19. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17: 668-675.
20. Rodenhuis S, Van de Wetering ML, Mooi WJ, et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987; 317: 929-935.
21. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-565.
22. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-smallcell lung cancer patients. Oncogene 1993; 8: 2.407-2.412.
23. Mitsudomi T, Viallet J, Mulshine JL, et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991; 6: 1.353-1.362.
24. Koo HM, Monks A, Mikheev A, et al. Enhanced sensitivity to 1-â-D-arabinofiranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring acti vated ras oncogenes. Cancer Res 1996; 56: 5.211-5.216.
25. Koo HM, McWilliams MJ, Alvord WG, Vande Woude GF. Ras oncogene-induced sensitization to 1-â-D-arabinofuranosylcytosine. Cancer Res 1999; 59: 6.057-6.062.
26. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91: 2.032-2.038.
27. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996; 347: 649-653.
28. Clark EA, Golub TR, Lander ES, et al. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535.
29. Del Peso L, Hernández-Alcoceba R, Embade N, et al. Rho proteins induce metastatic properties in vivo. Oncogene 1997; 15: 3.047-3.057.
30. Nielsen LL, Shi B, Hajian G, et al. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res 1999; 59: 5.896-5.901.
31. O'Dwyer PJ, Stevenson JP, Gallagher M, et al. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 1999; 5: 3.977-3.982.
32. Sánchez-Céspedes M, Reed AL, Buta M, et al. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 1999; 18: 5.843-5.849.
33. Rosell R, Monzó M, Jassem J, et al. High frequency of p53 mutations in non-small cell lung cancer detected with yeast functional assay. Nowotwory 1999; 49: 47-54.
34. Kato S, Shimada A, Osada M, et al. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters. Cancer Res 1999; 59: 5.908-5.911.
35. Nadioler-Eckersberger D, Kappel S, Mittlböck M, et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based 20 neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117: 744-750.
36. Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced nonsmall cell lung cancer. Cancer Res 1995; 55: 5.038-5.042.
37. Wang Y, Blandino G, Oren M, Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 1998; 17: 1.923-1.930.
38. Giannakakou P, Sackett DL, Kang Y-K, et al. Paclitaxel-resistant human ovarian cancer cells have mutant â-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17.118-17.125.
39. Rosell R, González-Larriba JL, Alberola V, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Sem Oncol 1995; 22 (Supl 14): 12-18.
40. Blagosklonny MV, Kiannakakou P, El-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57: 130-135.
41. Monzó M, Rosell R, Sánchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999; 17: 1.786-1.793.
42. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4.285-4.300.
43. Zhang CC, Yang J-M, White E. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 1998; 16: 1.617-1.624.
44. Veitia R, Bissery M-C, Martinez C, Fellous A. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice. Br J Cancer 1998; 78: 871-877.
45. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cell to chemotherapy. Oncogene 1999; 18: 477-485.
46. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-offunction phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA 1998; 95: 5.166-5.171.
47. Cho Y, Gorina S, Jeffrey P, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
48. Zhou X, Wang XW, Xu L, et al. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Res 1999; 59: 843-848.
49. De Anta JM, Jassem E, Rosell R, et al. TP53 mutational pattern in spanish and polish non-small-cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 1997; 15: 2.951-2.958.
50. Hashimoto T, Tokuchi Y, Hayashi M, et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage nonsmall-cell lung carcinomas. Cancer Res 1999; 59: 5.572-5.577.
51. Tomizawa Y, Kohno T, Fujita T, et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small-cell lung carcinoma. Oncogene 1999; 18: 1.007-1.014.
52. Jassem E, Rosell R, Monzo M. Prognostic relevance of p53 gene mutations in non-small cell lung cancer: adverse effect in adenocarcinoma. Clin Lung Cancer (submitted).
53. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999; 91: 1.758-1.764.
54. Ahrendt SA, Halachmi S, Chow JT, et al. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci USA 1999; 96: 7.382-7.387.
55. Nguyen DM, Chen A, Mixon A, Schrump DS. Sequence-dependent enhancement of paclitaxel toxicity in non-small-cell lung cancer by 17-allylamino 17-de methoxygeldanamycin. J Thorac Cardiovasc Surg 1999; 118: 908-915.
56. Tsai CM, Yu D, Chang KT, et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst 1995; 87: 682-684.
57. Taylor ST, Hickman JA, Dive C. Epigenetic determinants of resistance to etoposide regulation of BC1-XL and bax by tumor microenvironmental factors. J Natl Cancer Inst 2000; 92: 18-23.
58. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Ntl Acad Sci USA 1995; 92: 4.507-4.511.
59. Taron M, Plasencia M, Guillot M, et al. Comparative analysis of thymidylate synthase expression and cell cycle profile after topotecan or irinotecan ± 5-fluorouracil exposure. Proc AACR 1999; 40: 400 (abstr 2646).
60. Hengstler JG, Lange J, Kett A, et al. Contribution of c-erbB-2 and topoisomerase IIá to chemoresistance in ovarian cancer. Cancer Res 1999; 59: 3.206-3.214.
61. Plasencia C, Taron M, Abad A, Rosell R. Synergism of oxaliplatin (oxa) with either 5-fluorouracil (5FU) or topoisomerase I inhibitor in sensitive and 5FU-resistant colorectal cell lines is independent of DNA-mismatch repair and p53 status. ASCO 2000; 19: 204a (abstr 793).
62. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Sem Oncol 1998; 25 (Supl 5): 4-12.
63. Esteller M, Baylin SB, Herman JG. Beyond the genetic lesions: gene inactivation by promoter hypermethylation in human cancer. Rev Oncologia 2000; 2: 61-66.
64. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-797.
65. Esteller M, Sánchez-Céspedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from nonsmall-cell lung cancer patients. Cancer Res 1999; 59: 67-70.
66. Deng G, Chen A, Hong J, et al. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999; 59: 2.029-2.033.
67. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6.870-6.875.
68. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52.
69. Mackay HJ, Cameron D, Rahilly M, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18: 87-93.
70. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associatcd with the CpG island methylator phenotype. Cancer Res 1999; 59: 5.438-5.442.
71. Strobel T, Kraeft SK, Chen LB, et al. Bax expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for bax during chemotherapy induced cell death. Cancer Res 1998; 58: 4.776-4.781.
72. Strobel T, Tai YT, Korsmeyer S, et al. BAD partly reverses paclitaxel resistance in human ovarian cancer cells. Oncogene 1998; 17: 2.419-2.427.
73. Escuin D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Clinical Lung Cancer 1999; 1: 138-143.
74. Monzó M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2.100-2.104.
75. Mahotka C, Wenzel M, Springer E, et al. Survivin-ÄEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6.097-6.102.
76. Singh KK, Russell J, Sigala B, et al. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999; 18: 6.641-6.646.
77. González-Garay ML, Chang L, Blade K, et al. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 1999; 274: 23.875-23.882.
78. Nogales E, Wolf SG, Downing KH. Structure of the αβ tubulin dimer by electron crystallography. Nature Palabras clave: resistencia al paclitaxel, dinámica de los microtúbulos, mutaciones del ras, p53, mutaciones de la tubulina.